What Is The Predicted Revenue Outlook For The Global Direct Oral Anticoagulants (DOACs) Device Market To Surpass $45.64 Billion?
Uncover key drivers, emerging technologies, and competitive movements shaping the direct oral anticoagulants (doacs) device market from 2025–2034 with trusted insights from The Business Research Company
What Is The Projected Valuation Of The Direct Oral Anticoagulants (DOACs) Device Market In The Coming Years?
The market size for direct oral anticoagulants (DOACs) devices has experienced robust growth in recent years. It is anticipated to expand from $30.10 billion in 2024 to $32.80 billion in 2025, at a compound annual growth rate (CAGR) of 9.0%. This historical growth can be linked to factors such as the increasing prevalence of cardiovascular disorders, a rising incidence of atrial fibrillation, enhanced awareness regarding stroke prevention, an increase in anticoagulant prescriptions, and the expanding geriatric population.
The direct oral anticoagulants (DOACs) device market size is projected to experience substantial expansion in the coming years. This market is anticipated to reach $45.65 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 8.6%. Factors contributing to this growth during the forecast period include the increasing adoption of personalized medical approaches, a heightened preference for managing anticoagulation at home, a growing need for quick diagnostic instruments, increased understanding of stroke prevention, and the development of healthcare facilities in developing economies. Key trends expected during this period encompass the incorporation of smart sensors into monitoring devices, the creation of point-of-care testing solutions for direct oral anticoagulants, ongoing advancements in drug delivery methods, their integration into standard clinical practices, and technological improvements in tools designed to enhance patient adherence.
Get A Free Sample Of The Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=27281&type=smp
Which Market Dynamics Are Playing A Critical Role In The Growth Of The Direct Oral Anticoagulants (DOACs) Device Market?
The direct oral anticoagulants (DOACs) device market is projected to expand due to the escalating prevalence of cardiovascular disorders. These disorders encompass various conditions impacting the heart and blood vessels, frequently leading to issues such as heart attacks, strokes, or other circulatory problems. The rise in cardiovascular disorders is attributed to increasingly sedentary lifestyles, which contribute to weight gain, elevated blood pressure, and a gradual weakening of cardiovascular function. Direct oral anticoagulants (DOACs) play a vital role in managing cardiovascular disorders by effectively reducing the risk of stroke and blood clots in patients with atrial fibrillation, providing reliable anticoagulation without the necessity of frequent blood tests. For instance, according to the American Heart Association in January 2025, cardiovascular disease was responsible for 941,652 deaths in the US in 2022, which is over 10,000 more than the 931,578 deaths attributed to it in 2021. Consequently, the increasing prevalence of cardiovascular disorders is propelling the growth of the direct oral anticoagulants (DOACs) device market.
Which Sub-Segments Are Driving Growth Within The Direct Oral Anticoagulants (DOACs) Device Market?
The direct oral anticoagulants (DOACs) device market covered in this report is segmented
1) By Product: Factor Xa Inhibitors, Direct Thrombin Inhibitors
2) By Disease: Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, Heart Attacks, Post-Surgical Thromboprophylaxis, Other Diseases
3) By Application: Stroke Prevention, Venous Thromboembolism Prevention, Treatment Of Acute Thrombotic Events, Long-Term Prophylaxis, Other Applications
4) By End User: Hospitals, Ambulatory Surgical Centers, Specialty Clinics, Homecare Settings, Other End Users
Subsegments:
1) By Factor Xa Inhibitors: Rivaroxaban Monitoring Devices, Apixaban Monitoring Devices, Edoxaban Monitoring Devices, Betrixaban Monitoring Devices
2) By Direct Thrombin Inhibitors: Dabigatran Etexilate, Dabigatran Mesylate
What Future-Focused Trends Are Anticipated In The Direct Oral Anticoagulants (DOACs) Device Market?
Leading companies active in the direct oral anticoagulants (DOACs) device market are channeling efforts into developing advanced solutions, including automated coagulation assays, to enhance the accuracy, efficiency, and uniformity of monitoring direct oral anticoagulant levels in clinical laboratories. Automated coagulation assays are laboratory procedures performed by machines that gauge the rate at which blood clots, aiding in the identification of bleeding or clotting disorders. An example of this is Roche Holding AG, a pharmaceutical company from Switzerland, which in February 2024, unveiled three new coagulation tests specifically designed for Factor Xa inhibitors. These tests empower clinicians to more precisely evaluate the anticoagulation state of patients on direct Factor Xa inhibitors such as rivaroxaban and apixaban. They contribute to informed clinical decisions by accurately quantifying the anti-Xa activity of apixaban, edoxaban, rivaroxaban, and heparin in critical scenarios like hemorrhage, overdose, or urgent surgical interventions. Utilizing Roche’s unique reagent cassette technology on cobas t analyzers, these automated analyses deliver high-quality outcomes, minimize manual handling, and streamline laboratory operational efficiency.
Which Players Are Shaping The Competitive Landscape Of The Direct Oral Anticoagulants (DOACs) Device Market?
Major companies operating in the direct oral anticoagulants (DOACs) device market are Pfizer Inc., Roche Diagnostics Corporation, Bristol-Myers Squibb Company, Siemens Healthcare GmbH, Becton Dickinson And Company, Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Limited, Daiichi Sankyo Co. Ltd, Sysmex Corporation, Dr. Reddy’s Laboratories Limited, Werfen S.A., Alembic Pharmaceuticals Limited, Diagnostica Stago SAS, Helena Laboratories Corporation, iLine Microsystems S.L., Technoclone GmbH, Anthos Therapeutics Inc., FLoBio LLC, Perosphere Technologies Inc., and DOASENSE GmbH.
Access The Complete Report Here:
How Do Regional Dynamics Influence The Direct Oral Anticoagulants (DOACs) Device Market Performance?
North America was the largest region in the direct oral anticoagulants (DOACs) device market in 2024. The regions covered in the direct oral anticoagulants (DOACs) device market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Customize Your Report Here:
https://www.thebusinessresearchcompany.com/customise?id=27281&type=smp
Browse Through More Reports Similar to the Global Direct Oral Anticoagulants (DOACs) Device Market 2025, By The Business Research Company
Financial Services Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/financial-services-global-market-report
Financial Analytics Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/financial-analytics-global-market-report
Machine Learning Ml In The Pharmaceutical Industry Global Market Report 2025
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
